SOPs: harmonization of protocols for the manual tracing of the hippocampus development and validation of a unified standard protocol: an eadc-adni joint effort
The care of Alzheimer Disease (AD) patients will change radically in the next few years. At present, drugs that by contrasting the accumulation of amyloid (the toxic substance hold as the responsible of the disease) may significantly delay autonomy loss are at an advanced testing stage. Diagnostic procedures able to detect the disease in its early stage, when the patient is still self-sufficient and with a good quality of life, are therefore of critical relevance. It has recently been shown that early diagnosis is feasible through sophisticated imaging exams able to detect some disease’s markers.
An acknowledged marker for the Alzheimer’s disease is the atrophy of the hippocampus, a structure belonging to the medial temporal lobe. The volume of this structure can be measured in vivo through manual outlining Magnetic Resonance images by an expert tracer.
Unfortunately, these imaging exams are now performed only in research laboratories and following heterogeneous procedures.
Different anatomical boundaries results in different estimates across laboratories worldwide, thus preventing the comparison of different studies and the transfer of the marker to the clinical practice for the diagnosis.
Aim of this project, that involves the major international specialists of hippocampal tracing in AD, is to harmonize the available protocols for the manual tracing of the hippocampus in order to create a standard and shared protocol. This protocol will allow to promote the dissemination of this advanced diagnostic tool to a broader patient base.
THE WORKING GROUP
|F Barkhof /Ph Scheltens, Amsterdam||B Dubois / S Leherici, Paris|
|N. Fox, London||GB Frisoni, Brescia||H Hampel, Dublin|
|H Soininen, Kuopio||S Teipel, Rostock||L-O Wahlund, Stockholm|
US ADNI centres
|G Bartzokis, UCLA, CA||D Bennett, Rush ADC, Chicago, ILL|
|J Csernansky, Northwestern U, WA||C DeCarli, UC Davis, CA||M De Leon, New York, NY|
|CR Jack, Rochester, MN||J Kaye, Portland, OR||R Killiany, Boston USM, MA|
|PM Thompson, LoNI, UCLA, CA||M Weiner / S Mueller, UCSF, CA|
Other clinical centres
|J O’Brien, Newcastle, UK||R Camicioli, Univ. Alberta, Canada|
|J Pantel, Univ. Frankfurt/Mein,GER||J Pruessner, McGill Univ, QC, Canada|
|Rotterdam Scan Study, M Breteler/T den Heijer||PATH through life, P Sachdev/JJ Maller|
BOARDS. The coordinator will be supported by: (i) co-Principal Investigator Clifford Jack, MR core leader of ADNI, (ii) a statistical working group headed by Simon Duchesne, Laval University, Canada, and including Louis Collins, MNI, McGill, Montreal and Patrizio Pasqualetti, AFaR, Roma; (iii) an advisory board including EADC PIs Bruno Vellas, Toulouse, France and Bengt Winblad, Stockholm, Sweden; ADNI PI Mike Weiner, UCSF, US; (iv) a clinical advisor, Pieter Jelle Visser, Maastricht, The Netherlands; (v) a population studies advisor, Lenore Launer, NIA, Bethesda, (vi) a dissemination and education advisor, Gunhild Waldemar, Copenhagen, Denmark; and (vii) industrial advisors, i.e. representatives from the sponsoring pharma companies.